Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Integrated Chinese and Western medicine for amnestic mild cognitive impairment
ChiCTR2100051030Phase 4Recruiting
- Sponsor
- Shandong Provincial Hospital Affiliated to Shandong First Medical University
- Start
- Oct 2021
- Modality
- Microbiome-Derived Products → Microbiome Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of sodium oligomannate and Yangxueqingnao in amnestic mild cognitive impairment (MCI) and Alzheimer's disease (AD) (3 arms), sponsored by Shandong Provincial Hospital Affiliated to Shandong First Medical University. Primary endpoint: Montreal Cognitive Assessment score. Started Oct 2021; status: recruiting.
02
Drugs
sodium oligomannateYangxueqingnao
03
Conditions
amnestic mild cognitive impairment (MCI)Alzheimer's disease (AD)
Beyond the preview
Go deeper on ChiCTR2100051030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051030.